Target intelligence / Profile preview

28S ribosomal protein S16, mitochondrial (MRPS16)

Target
MRPS16
Molecular classification
Ribosomal protein, Structural protein, Member of the S16P ribosomal protein family
01

Overview

28S ribosomal protein S16, mitochondrial (MRPS16), is a nuclear-encoded protein crucial for the assembly and function of the mitochondrial small ribosomal subunit (28S)[1][6]. Unlike prokaryotic ribosomes, mammalian mitoribosomes have distinct protein-to-RNA ratios and lack some rRNA components. MRPS16 is highly conserved, especially between yeast and mammalian mitochondria, reflecting its essential role in mitochondrial protein synthesis. It participates in the translation of mitochondrial-encoded proteins necessary for oxidative phosphorylation, the process by which mitochondrial energy is generated[1][5]. Mutations in MRPS16 disrupt mitochondrial translation and lead to severe multisystem mitochondrial diseases, including combined oxidative phosphorylation deficiency 2 (COXPD2), and have been linked to lethal neonatal syndromes involving lactic acidosis and neurological deficits[2][5]. MRPS16 is not a classical therapeutic target, but it is essential for cellular energy metabolism and mitochondrial function.

Other names
Small ribosomal subunit protein bS16mMRPS16RPMS16CGI-132MRP-S16S16mtbS16m28S ribosomal protein S16, mitochondrialCOXPD2
02

Mechanism of action

Not applicable; MRPS16 is not a direct drug target.

03

Biological functions

Structural constituent of the 28S small subunit of mitochondrial ribosomeMitochondrial translation (protein synthesis in mitochondria)
04

Disease associations

Combined oxidative phosphorylation deficiency 2 (COXPD2)Progressive leukoencephalopathy with ovarian failureMutations cause severe, often fatal mitochondrial translation defects, lactic acidosis, and multisystem disease, including agenesis of the corpus callosum and dysmorphism
05

Safety considerations

Not applicable; MRPS16 is not a pharmacological target. However, deficiency/mutation leads to severe disease and diagnostic challenges
06

Biomarkers

Genetic testing for MRPS16 mutations may serve as a diagnostic biomarker for mitochondrial disorders (specifically COXPD2)

Beyond the preview

Go deeper on 28S ribosomal protein S16, mitochondrial (MRPS16).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 28S ribosomal protein S16, mitochondrial (MRPS16).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call